C. J. Arora 1 , D.D. Murrell2
Alopecia areata is a chronic inﬂammatory, autoimmune disease that results in non-scarring hair loss in various patches of the scalp. Although AA is neither life threaten- ing nor painful, it is associated with a degree of anxiety and psychological distress, that reduces the patients’ qual- ity of life. Various treatment options are available for AA, including oral and intralesional corticosteroids, minoxidil, and immunosuppressants like methotrexate and cyclospor- ine. As the disease course itself is unpredictable, all these options have limited efﬁcacy. Janus Kinase (JAK) inhibitors block the function of the JAK family of enzymes. These enzymes play an important role in immunity and chronic inﬂammation, as they mediate signal transduction from cytokine receptors on the cell surface, which in turn regu- lates gene expression. JAK inhibitors have been used effec- tively to treat autoimmune disorders such as rheumatoid arthritis and psoriasis. Its efﬁcacy in the treatment of alopecia areata has been evaluated by several case series. In this systematic review, we attempt to collate all the evidence available in literature, on the efﬁcacy and safety of JAK inhibitors in the treatment of alopecia areata, and its variants.
A non-interventional-prospective-12-month study to characterise REAL-life effectiveness and treatmentpatterns of secukinumab, and current standard-of-care of chronic plaque psoriasis in Asia-Pacific & MiddleEast